Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV.
Matthews RP, Ankrom W, Friedman E, Jackson Rudd D, Liu Y, Mogg R, Panebianco D, De Lepeleire I, Petkova M, Grobler JA, Stoch SA, Iwamoto M. Matthews RP, et al. Among authors: grobler ja. Clin Transl Sci. 2021 Sep;14(5):1935-1944. doi: 10.1111/cts.13048. Epub 2021 Aug 31. Clin Transl Sci. 2021. PMID: 34463432 Free PMC article. Clinical Trial.
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial.
Schürmann D, Rudd DJ, Zhang S, De Lepeleire I, Robberechts M, Friedman E, Keicher C, Hüser A, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Matthews RP. Schürmann D, et al. Among authors: grobler ja. Lancet HIV. 2020 Mar;7(3):e164-e172. doi: 10.1016/S2352-3018(19)30372-8. Epub 2020 Jan 3. Lancet HIV. 2020. PMID: 31911147 Clinical Trial.
Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week.
Schürmann D, Jackson Rudd D, Schaeffer A, De Lepeleire I, Friedman EJ, Robberechts M, Zhang S, Liu Y, Kandala B, Keicher C, Däumer M, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Ankrom W. Schürmann D, et al. Among authors: grobler ja. J Acquir Immune Defic Syndr. 2022 Feb 1;89(2):191-198. doi: 10.1097/QAI.0000000000002834. J Acquir Immune Defic Syndr. 2022. PMID: 34654041 Free PMC article. Clinical Trial.
Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).
Diamond TL, Ngo W, Xu M, Goh SL, Rodriguez S, Lai MT, Asante-Appiah E, Grobler JA. Diamond TL, et al. Among authors: grobler ja. Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0013322. doi: 10.1128/aac.00133-22. Epub 2022 May 12. Antimicrob Agents Chemother. 2022. PMID: 35546110 Free PMC article.
Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention.
Barrett SE, Teller RS, Forster SP, Li L, Mackey MA, Skomski D, Yang Z, Fillgrove KL, Doto GJ, Wood SL, Lebron J, Grobler JA, Sanchez RI, Liu Z, Lu B, Niu T, Sun L, Gindy ME. Barrett SE, et al. Among authors: grobler ja. Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01058-18. doi: 10.1128/AAC.01058-18. Print 2018 Oct. Antimicrob Agents Chemother. 2018. PMID: 30012772 Free PMC article.
68 results